ResMed (FRA:RMEA) 3-Year FCF Growth Rate : -7.40% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ResMed 3-Year FCF Growth Rate?

ResMed's Free Cash Flow per Share for the three months ended in Dec. 2023 was €0.15.

During the past 12 months, ResMed's average Free Cash Flow per Share Growth Rate was 324.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -7.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -2.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of ResMed was 110.90% per year. The lowest was -37.90% per year. And the median was 14.40% per year.

Competitive Comparison of ResMed's 3-Year FCF Growth Rate

For the Medical Instruments & Supplies subindustry, ResMed's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ResMed's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where ResMed's 3-Year FCF Growth Rate falls into.

ResMed 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

ResMed (FRA:RMEA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

ResMed 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of ResMed's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (FRA:RMEA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RMEA) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMD:Mexico R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (FRA:RMEA) Headlines

No Headlines